145 related articles for article (PubMed ID: 22394323)
21. Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
Van den Bergh A; Van Hemelryck S; Bevernage J; Van Peer A; Brewster M; Mackie C; Mannaert E
Mol Pharm; 2018 Jul; 15(7):2633-2645. PubMed ID: 29799758
[TBL] [Abstract][Full Text] [Related]
22. High throughput microsomal stability assay for insoluble compounds.
Di L; Kerns EH; Li SQ; Petusky SL
Int J Pharm; 2006 Jul; 317(1):54-60. PubMed ID: 16621364
[TBL] [Abstract][Full Text] [Related]
23. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
24. Developing early formulations: practice and perspective.
Li P; Zhao L
Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
[TBL] [Abstract][Full Text] [Related]
25. Predicting biopharmaceutical performance of oral drug candidates - Extending the volume to dissolve applied dose concept.
Muenster U; Mueck W; van der Mey D; Schlemmer KH; Greschat-Schade S; Haerter M; Pelzetter C; Pruemper C; Verlage J; Göller AH; Ohm A
Eur J Pharm Biopharm; 2016 May; 102():191-201. PubMed ID: 26955751
[TBL] [Abstract][Full Text] [Related]
26. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
27. Using absorption simulation and gastric pH modulated dog model for formulation development to overcome achlorhydria effect.
Mitra A; Kesisoglou F; Beauchamp M; Zhu W; Chiti F; Wu Y
Mol Pharm; 2011 Dec; 8(6):2216-23. PubMed ID: 21981752
[TBL] [Abstract][Full Text] [Related]
28. Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing.
Shanbhag A; Rabel S; Nauka E; Casadevall G; Shivanand P; Eichenbaum G; Mansky P
Int J Pharm; 2008 Mar; 351(1-2):209-18. PubMed ID: 18054181
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in intravenous delivery of poorly water-soluble compounds.
Shi Y; Porter W; Merdan T; Li LC
Expert Opin Drug Deliv; 2009 Dec; 6(12):1261-82. PubMed ID: 19941409
[TBL] [Abstract][Full Text] [Related]
30. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption.
Beig A; Miller JM; Dahan A
Eur J Pharm Biopharm; 2012 Jun; 81(2):386-91. PubMed ID: 22387337
[TBL] [Abstract][Full Text] [Related]
31. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.
Linn M; Collnot EM; Djuric D; Hempel K; Fabian E; Kolter K; Lehr CM
Eur J Pharm Sci; 2012 Feb; 45(3):336-43. PubMed ID: 22172603
[TBL] [Abstract][Full Text] [Related]
32. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models.
Dokoumetzidis A; Kalantzi L; Fotaki N
Expert Opin Drug Metab Toxicol; 2007 Aug; 3(4):491-505. PubMed ID: 17696801
[TBL] [Abstract][Full Text] [Related]
33. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
Pouton CW; Porter CJ
Adv Drug Deliv Rev; 2008 Mar; 60(6):625-37. PubMed ID: 18068260
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME).
Dai WG; Dong LC; Shi X; Nguyen J; Evans J; Xu Y; Creasey AA
J Pharm Sci; 2007 Nov; 96(11):2957-69. PubMed ID: 17705287
[TBL] [Abstract][Full Text] [Related]
35. A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development.
Sigfridsson K; Nordmark A; Theilig S; Lindahl A
Drug Dev Ind Pharm; 2011 Feb; 37(2):185-92. PubMed ID: 20653464
[TBL] [Abstract][Full Text] [Related]
36. Selection of the most suitable dissolution method for an extended release formulation based on IVIVC level A obtained on cynomolgus monkey.
Scheubel E; Adamy L; Hoffart V; Cardot JM
Drug Dev Ind Pharm; 2010 Nov; 36(11):1320-9. PubMed ID: 20849348
[TBL] [Abstract][Full Text] [Related]
37. Systemic concentrations can limit the oral absorption of poorly soluble drugs: an investigation of non-sink permeation using physiologically based pharmacokinetic modeling.
Chiang PC; La H; Zhang H; Wong H
Mol Pharm; 2013 Nov; 10(11):3980-8. PubMed ID: 23611122
[TBL] [Abstract][Full Text] [Related]
38. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs.
Hu L; Tang X; Cui F
J Pharm Pharmacol; 2004 Dec; 56(12):1527-35. PubMed ID: 15563759
[TBL] [Abstract][Full Text] [Related]
39. Methodology for phase selection of a weak basic drug candidate, utilizing kinetic solubility profiles in bio-relevant media.
Furukawa S; Zhao C; Ohki Y
Eur J Pharm Biopharm; 2010 Feb; 74(2):298-303. PubMed ID: 19815062
[TBL] [Abstract][Full Text] [Related]
40. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation.
Pathak SM; Musmade P; Dengle S; Karthik A; Bhat K; Udupa N
Eur J Pharm Sci; 2010 Nov; 41(3-4):440-51. PubMed ID: 20656025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
